P-4: Mechanisms by Which the T1 Insulin-like Growth Factor Inhibition Enhances
P-4: Mechanisms by Which the T1 Insulin-like Growth Factor Inhibition Enhances
批准号:
8130549
负责人:
Stephen R. Plymate
金额:
$29.15万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2012-08-31
关键词:
AffectAndrogen ReceptorAndrogensAntibodiesApoptosisBRCA1 geneCastrationCell NucleusClinicalComplementary DNADataDiseaseGenetic TranscriptionGoalsGrowth FactorGrowth Factor InhibitionHumanLaboratoriesLocalized DiseaseMalignant neoplasm of prostateModalityModelingMonoclonal AntibodiesNeoadjuvant TherapyNuclearNuclear ImportNuclear TranslocationPathologicPatientsPatternPeptidesPhasePhenotypePhosphorylationPhosphorylation InhibitionPhosphorylation SitePre-Clinical ModelProstatectomyReceptor Protein-Tyrosine KinasesReceptor SignalingRecurrent diseaseSignal TransductionSomatomedinsTissuescofactordeprivationhigh riskhuman monoclonal antibodieshuman tissueimprovedmenmouse modelprogramsreceptor expressionresponsetumortumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The lethal phenotype of prostate cancer is termed androgen-independent (Al), because it develops
following castration in the presence of very low levels of androgen in men or undetectable androgen
levels in mouse models. It has been suggested that peptide growth factors, e.g.insulin-like growth
factors (IGF) signaling through the IGF tyrosine kinase receptor (IGF-IR), drive the Al phenotype.
Recent data clearly demonstrates that androgen receptor (AR) expression is increased in models of Al
disease and that in human tissue the AR remains primarily in the nucleus after castration. We have
shown inhibition of IGF-IR signaling, with a fully human IGF-IR monoclonal antibody, in androgen-
dependent (AD) and Al disease decreases nuclear AR, modifies the AR transcriptional program, and
delays emergence of Al disease following castration. In this proposal we will determine the
mechanisms of the IGF/AR interaction and efficacy of inhibition of these interactions on human
tumors. Hypothesis: Insulin-like growth factor signaling contributes to progression of androgen-
dependent [1] and androgen-insensitive [2] prostate cancer progression by enhancing AR nuclear
localization and AR signaling.
Aim 1. Determine effect of utilizing a human IGF-IR mab combined with castration in a phase
1b/ll neoadjuvant trial. This aim will exploit the potential use of IGF-IR blockade using hmabs in
association with castration as a potential treatment modality for prostate cancer. In this aim we will
utilize both clinical and tissue endpoints.
Aim 2. Aim 2. IGF signaling alters androgen receptor nuclear translocation in prostate cancer
through changes in AR phosphorylation. In this aim we will [1] determine if the change in
phosphorylation of the AR is associated with an alteration in nuclear import or export of the AR and [2]
determine which AR phosphorylation site altered by IGF-IR signaling is responsible for the change in
nuclear localization of the AR. [3].Determine the mechanism by which IGF-IR signaling alters AR
phosphorylation.
Aim 3. Determine the effects of changes in AR phosphorylation on association of AR co-
regulators and changes in AR transcription patterns. In the Preliminary Data, we note that
alteration of AR phosphorylation by inhibition of IGF-IR signaling results in an alteration of AR
associated co-factors. Most notably among the cofactprs were SMRT and BRCA1. In this aim we will
[1], perform a more completed assessment of associated co-regulators, [2] determine effects of co-
factors on AR translocation, and [3] determine effects of the associated co-factors on AR
transcriptional activity and the AR transcriptional program.
The relevance of this study to the goal of improving treatment for prostate cancer is that it will take the
laboratory data we have assembled demonstrating that the inhibition of the IGF-IR with a human
monoclonal antibody abrogates prostate cancer progression and apply it in a patient setting to
determine its potential efficacy in clinical disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer
-
批准号:10455421
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Stephen R. Plymate
-
依托单位:
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer
-
批准号:10015557
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Stephen R. Plymate
-
依托单位:
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer
-
批准号:10620272
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Stephen R. Plymate
-
依托单位:
Development of Castration Resistance by Alternative AR Splicing
-
批准号:8475912
-
项目类别:
-
资助金额:$40.65万
-
财政年份:2013
-
负责人:Stephen R. Plymate
-
依托单位:
Mechanisms for the Transition to Castrate Resistant Prostate Cancer
-
批准号:8391557
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Stephen R. Plymate
-
依托单位:
Mechanisms for the Transition to Castrate Resistant Prostate Cancer
-
批准号:7921471
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Stephen R. Plymate
-
依托单位:
Mechanisms for the Transition to Castrate Resistant Prostate Cancer
-
批准号:7796470
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Stephen R. Plymate
-
依托单位:
Mechanisms for the Transition to Castrate Resistant Prostate Cancer
-
批准号:8195899
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Stephen R. Plymate
-
依托单位:
Mechanisms by Which the Type 1 Insulin-like Growth Factor Inhibition Enhances
-
批准号:7314894
-
项目类别:
-
资助金额:$25.65万
-
财政年份:2007
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7491225
-
项目类别:
-
资助金额:$61.77万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7233446
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7500646
-
项目类别:
-
资助金额:$5.46万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7288370
-
项目类别:
-
资助金额:$55.82万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Administration and Data Management Core
-
批准号:7244277
-
项目类别:
-
资助金额:$4.24万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7684857
-
项目类别:
-
资助金额:$91.39万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Significance of Microenvironment for Prostate Cancer Initiation and Progression
-
批准号:7900042
-
项目类别:
-
资助金额:$56.01万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Laminin Dysregulation and Prostate Cancer
-
批准号:7244273
-
项目类别:
-
资助金额:$16.48万
-
财政年份:2006
-
负责人:Stephen R. Plymate
-
依托单位:
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost
-
批准号:7713780
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2002
-
负责人:Stephen R. Plymate
-
依托单位:
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost
-
批准号:8303431
-
项目类别:
-
资助金额:$30.47万
-
财政年份:2002
-
负责人:Stephen R. Plymate
-
依托单位:
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost
-
批准号:8518249
-
项目类别:
-
资助金额:$27.92万
-
财政年份:2002
-
负责人:Stephen R. Plymate
-
依托单位:
海外基金